ipid target achievement in high risk patients with Coronary Heart Disease (DYSIS II ACS/CHD) - Dysis-II

Merck Co Inc0 个研究点目标入组 10,500 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•DYSIS II ACS
•Age >= 18 years
•Hospitalized for acute coronary syndrome (ACS) (ST segment elevation myocardial infarction (STEMI), left bundle branch block (LBBB), Non-ST elevated myocardial infarction (NSTEMI), unstable angina) at time of enrolment
•Full lipid profile available based on blood drawn within 24 hours of admission to the hospital.
•On lipid-modifying therapy (LMT) for equal to or more than 3 months at time of enrolment, or NOT at all on LMT.
•DYSIS II CHD
•Age >= 18 years
•Documented CHD by at least one of the following:
•o coronary angiography (stenosis >50%)
•o cardiac computed tomography (CT) (stenosis > 50%)
•o prior percutaneous coronary intervention (PCI) or prior coronary artery bypass graft (CABG)
•o history of ACS >3 months prior to enrolment
•o Complete fasting lipid profile 0-12 months prior to enrollment while on lipid modifying therapy (LMT) for equal to or more than 3 months or not at all on LMT

•DYSIS II ACS
•Patients treated with lipid-modifying therapy for more than 0 but less than 3 months at the time of enrolment
•DYSIS II CHD
•History of ACS within 3 months prior to enrollment
•Participation in DYSIS II ACS

发起方